TY - JOUR
T1 - Nanotechnology in cancer therapy
AU - Aslan, Burcu
AU - Ozpolat, Bulent
AU - Sood, Anil K.
AU - Lopez-Berestein, Gabriel
N1 - Funding Information:
This work was supported in-part by CPRIT (RP120406 and RP120214), National Institutes of Health (CA093459, U54CA151668, U54CA096300, UH2TR000943, P50 CA083639, P50 CA098258, R44GM084552, R21CA167505 and R01CA151372), DOD (W81XWH-09-1-0385, OC073399, W81XWH-10-1-0158 and BC085265), the Marcus Foundation, the Blanton-Davis Ovarian Cancer Research Program, and the Betty Ann Asche Murray Distinguished Professorship.
PY - 2013/12
Y1 - 2013/12
N2 - Cancer is one of the major causes of mortality worldwide and advanced techniques for therapy are urgently needed. The development of novel nanomaterials and nanocarriers has allowed a major drive to improve drug delivery in cancer. The major aim of most nanocarrier applications has been to protect the drug from rapid degradation after systemic delivery and allowing it to reach tumor site at therapeutic concentrations, meanwhile avoiding drug delivery to normal sites as much as possible to reduce adverse effects. These nanocarriers are formulated to deliver drugs either by passive targeting, taking advantage of leaky tumor vasculature or by active targeting using ligands that increase tumoral uptake potentially resulting in enhanced antitumor efficacy, thus achieving a net improvement in therapeutic index. The rational design of nanoparticles plays a critical role since structural and physical characteristics, such as size, charge, shape, and surface characteristics determine the biodistribution, pharmacokinetics, internalization and safety of the drugs. In this review, we focus on several novel and improved strategies in nanocarrier design for cancer therapy.
AB - Cancer is one of the major causes of mortality worldwide and advanced techniques for therapy are urgently needed. The development of novel nanomaterials and nanocarriers has allowed a major drive to improve drug delivery in cancer. The major aim of most nanocarrier applications has been to protect the drug from rapid degradation after systemic delivery and allowing it to reach tumor site at therapeutic concentrations, meanwhile avoiding drug delivery to normal sites as much as possible to reduce adverse effects. These nanocarriers are formulated to deliver drugs either by passive targeting, taking advantage of leaky tumor vasculature or by active targeting using ligands that increase tumoral uptake potentially resulting in enhanced antitumor efficacy, thus achieving a net improvement in therapeutic index. The rational design of nanoparticles plays a critical role since structural and physical characteristics, such as size, charge, shape, and surface characteristics determine the biodistribution, pharmacokinetics, internalization and safety of the drugs. In this review, we focus on several novel and improved strategies in nanocarrier design for cancer therapy.
KW - Cancer therapy
KW - Drug delivery
KW - Nanomedicine
KW - Nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=84887237617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887237617&partnerID=8YFLogxK
U2 - 10.3109/1061186X.2013.837469
DO - 10.3109/1061186X.2013.837469
M3 - Review article
C2 - 24079419
AN - SCOPUS:84887237617
SN - 1061-186X
VL - 21
SP - 904
EP - 913
JO - Journal of Drug Targeting
JF - Journal of Drug Targeting
IS - 10
ER -